John Gnann to Drug Therapy, Combination
This is a "connection" page, showing publications John Gnann has written about Drug Therapy, Combination.
Connection Strength
0.054
-
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 2004 Nov; 64(2):103-11.
Score: 0.013
-
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003 Jun; 8(3):183-90.
Score: 0.012
-
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report. Ann Intern Med. 2000 Sep 19; 133(6):435-8.
Score: 0.010
-
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996 Sep 01; 125(5):376-83.
Score: 0.007
-
Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res. 1996 Jan; 29(1):67-8.
Score: 0.007
-
Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days. J Infect Dis. 1991 Feb; 163(2):325-30.
Score: 0.005